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E-mail address: Cambierj@NJHEALTH.org (J.C. CamImmunoreceptor signals must be appropriately transduced and regulated to achieve effective
immunity while controlling inﬂammation and autoimmunity. It is generally held that these pro-
cesses are mediated by the interplay of distinct activating and inhibitory receptors via conserved
activating (ITAM) and inhibitory (ITIM) signaling motifs. However, recent evidence indicates that
under certain conditions incomplete phosphorylation of ITAM tyrosines leads to inhibitory signal-
ing. This new regulatory function of ITAMs has been termed ITAMi (inhibitory ITAM). Here we dis-
cuss the potential molecular mechanisms of inhibitory signaling by ITAM-containing receptors.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The outcome of antigen receptor signaling is determined by a
complex network of activating and attendant regulatory signaling
circuitry. The balance of these signals determines cell fate and is
essential for generation of effective immunity, while controlling
inﬂammation and autoimmunity. The classical view of immune
receptor signaling and its regulation involves the interplay of sig-
nals transduced via receptors containing immunoreceptor tyro-
sine-based activation motif (ITAM) and distinct receptors
containing immunoreceptor tyrosine-based inhibition motifs
(ITIM). However, recent evidence suggests that more complex
mechanisms exist, wherein incomplete phosphorylation of ITAM
tyrosines may alter the output of signaling [1]. This inhibitory
function has been termed ITAMi (inhibitory ITAM). Interestingly,
studies in our own laboratory suggest that similar mechanisms
may be involved in maintenance of B cell anergy. More speciﬁcally,
the chronic antigen receptor signals that are required to sustain B
cell anergy drive monophosphorylation of BCR ITAMs (O’Neill andchemical Societies. Published by E
bier).Cambier, in preparation). Importantly, further studies suggest that
the distinguishing feature of this inhibitory signaling is the robust
activation of Src-family kinases. We suggest that it is monophos-
pho-ITAM ([P]1ITAM)-mediated activation of Src-family kinases
rather than some other intrinsic ITAM function that leads to inhib-
itory signaling. In support of this concept we have found that acti-
vation of Lck by aggregation of CD4 on T cells leads to
mechanistically similar inhibitory signaling that regulates TCR-
mediated T cell activation. In this brief review we will compare
and contrast these mechanisms and discuss the potential identity
of effectors of these inhibitory signals.
2. Immunoreceptor tyrosine-based signaling motifs
ITAMs are found in multisubunit immunoreceptors such as B-
cell and T-cell antigen receptors (BCRs and TCRs) and activating
Fc receptors (FcRs) [2,3]. ITAMs are characterized by content of
the consensus sequence YxxL/I-(x)6–8-YxxL/I (where x is any amino
acid) which mediates signal propagation by activation of Syk or
Zap70 tyrosine kinases [3,4]. Aggregation of ITAM-containing
receptors leads to phosphorylation of the ITAM tyrosines via Src-
family kinases. Dual phosphorylation of the conserved ITAM tyro-lsevier B.V. All rights reserved.
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tandem SH2 domains of Syk and/or ZAP-70 kinases (16). Recruit-
ment and activation of Syk and/or ZAP-70 leads to tyrosine phos-
phorylation-dependent activation of multiple downstream
pathways that drive activation, proliferation, differentiation and
survival [5]. ITAM monophosphorylation is not without functional
consequence. Aggregation-induced monophosphorylation of BCR
ITAMs leads to tyrosine phosphorylation of Lyn and a limited num-
ber of its downstream substrates consistent with kinase activation
[6].
ITIM-containing receptors are evolutionarily conserved mem-
brane proteins whose origin can be traced to the most primitive
metazoa [7]. The inhibitory function of ITIM-containing receptors
was ﬁrst deﬁned in the low afﬁnity immunoglobulin G (IgG) recep-
tor FccRIIB [8]. Most ITIMs contain the consensus sequence (I/V/L/
S)xYxx(L/V) which, when tyrosine phosphorylated, binds to the
SH2 domain-containing 5-inositol phosphatase SHIP-1 and SHIP-
2 and/or the SH2 domain containing tyrosine phosphatases SHP-
1 and SHP-2 [9,10]. While ITIM binding to SHPs strictly requires
Y2 hydrophobic residues due to presence of a hyphobic pocket
in the phosphatases, association with SHIPs does not and further
prefers L at the Y+2 position [11–13]. Once activated, SHIP-1/2
and SHP-1/2 dephosphorylate inositol phospholipids and tyrosyl-
phophorylated proteins, respectively, attenuating cell activation.3. Proximal events in B cell antigen receptor signaling
The BCR transduces signals via a disulﬁde-bonded heterodimer
of immunoglobulin a (Iga or CD79a) and immunoglobulin b (Igb or
CD79b) that is non-covalently associated with membrane bound
immunoglobulin (mIg) [14,15]. Aggregation of mIg–Iga/Igb com-
plexes leads to activation of associated Src-family kinases (Lyn in
most mature B cells) which then phosphorylate the two tyrosines
found in the single ITAM in each Iga and Igb chain [14,16]. As noted
above, dual phosphorylation of a single ITAM is required to gener-
ate the Syk/Zap70 docking site, and thereby promote activation of
the kinase [17]. One of the key Syk substrates is the adaptor mol-
ecule B-cell linker protein (BLNK) which when phosphorylated
serves as a scaffold for phospholipase C gamma (PLCc), Bruton’s
tyrosine kinase (Btk), GRB2/VAV and *Son of Sevenless (SOS) [18].
PI3K is activated by Lyn and Syk via parallel pathways. This oc-
curs by tyrosine phosphorylation and PI3K binding to the cytosolic
adaptor BCAP [19], and the membrane adaptor/coreceptor CD19
[20]. In addition to its direct function in PI3K activation, CD19
reportedly mediates the processive activation of Lyn creating a po-
sitive forward feeding loop [21] and this is predicted to enhance
positive signaling by recruiting Btk and VAV [22]. PI3K can also
be activated by a process involving direct binding to Lyn, thus
the processive CD19 activation of Lyn could further promote PI3K
activation [23].
PI3K mediates the production of phosphatidylinositol 3,4,5-tri-
phosphate (PtdIns(3,4,5)P3) from PtdIns(4,5)P2. PtdIns(3,4,5)P3 is a
critical lipid second messenger in BCR signaling, functioning in the
recruitment of multiple effectors to the membrane via binding to
their pleckstrin homology (PH) domains. These include Btk, VAV,
PDK1, Akt and PLCc. The precise temporal and functional relation-
ship of Btk and PLCY binding to BLNK and PtdIns(3,4,5)P3 is un-
clear. It seems likely that this is a stepwise process in which
binding to BLNK facilitates phosphorylation and activation by
receptor associated kinases, while subsequent binding to phospho-
lipids places them in apposition to their substrates. PLCc cleavage
of PtdIns(4,5)P2 yields Ins(1,4,5)P3 and diacylglycerol (DAG) which
trigger calcium release and stimulate various isoforms of Protein
Kinase C (PKC), respectively. Obviously, generation and accumula-tion of PtdIns(3,4,5)P3 is a critical step in the propagation of acti-
vating antigen receptor signals.
4. SHP-1 and SHIP-1 as mediators of both FcYRIIB and feedback
inhibition of BCR signaling
In view of the roles of protein tyrosine and inositol lipid phos-
phorylation in antigen receptor signaling, it is intuitive that this
process is regulated by inositol lipid and tyrosine phosphatases.
Phosphatases were ﬁrst implicated in regulation of antigen recep-
tor signaling in studies of the molecular basis of inhibitory signal-
ing by FcYRIIB [24]. It was found that synthetic phosphopeptides
constructed based on the cytoplasmic tail sequences of FccRIIB
known to be required for inhibitory function, bound to SHP-1
and SHP-2 [24]. These observations were later extended to SHIP-
1 [9,25,26], and it was shown that both SHP-1 deﬁcient (MeV)
and SHIP-1/ mice exhibited defects in FccRIIB signaling [9,27].
Interestingly, while SHIP-1 is the primary mediator of this signal,
the relative importance of SHP-1 and SHIP-1 appears to depend
on the efﬁciency of receptor crosslinking, with higher order cross-
linking evoking more SHP-1 function [12]. This may relate to the
fact the SHP-1 (but not SHIP) contains two SH2 domains that
may bridge phosphorylated ITIMs on apposing FcYRIIB. Occupancy
of both SHP-1 SH2 domains appears to be required for its activa-
tion by derepression [11].
The inhibitory activities of SHIP-1 and SHP-1 differ in more than
the fact that they have distinct substrates. Studies by Blery et al.
[28] demonstrated the ITIM-containing receptors that engage
SHP-1 function only at short range, inhibiting only receptors with
which they are co-aggregated. ITIM-containing receptors that en-
gage SHIP-1 are able to act in trans, inhibiting remotely stimulated
receptors. If SHP-1 is activated by derepression as discussed above,
inhibition would be limited to the reach of inhibitory receptor-
bound enzyme because it would only be active when tethered.
Long-range activity of SHIP-1 suggests that this effector is active
after dissociation from the inhibitory receptor. In addition to its
phosphatase domain, SHIP contains an amino-terminal SH2 do-
main, as well as proline-rich region and two NPxY motifs in its ex-
tended C terminal region. These domains mediate association with
several proteins, including CD150, Shc, SHP-2, Gab and Dok [29].
NPxY motifs of SHIP-1 are phosphorylated upon FcYRIIB stimula-
tion, and bind to the phosphotyrosine-binding domain (PTB) of
Downstream of kinase (Dok-1). This binding likely facilitates the
subsequent tyrosine phosphorylation of Dok-1. Phosphotyrosines
within Dok-1 are known to bind to the SHIP-1 SH2 domain [30].
Thus it is easy to imagine that the consequence of this stepwise
recruitment and tyrosine phosphorylation is formation of a biden-
tate complex of SHIP and Dok. Indeed, Dok is the primary phospho-
protein that co-precipitates with SHIP-1 in stimulated
lymphocytes (J.C.C. and P. Waterman, unpublished).
The question then arises, does Dok play a role in SHIP-1-medi-
ated trans-inhibitory signaling? It is noteworthy that Dok-1 con-
tains a PH domain that binds to PtdIns(3,4,5)P3 and could
therefore mediate targeting of SHIP-1/Dok-1 complexes to areas
of plasma membrane enriched in PtdIns(3,4,5)P3 [31]. This locali-
zation could facilitate SHIP-1 hydrolysis of PtdIns(3,4,5)P3 yielding
PtdIns(3,4,)P2. Consistent with this hypothesis, we have found in
ongoing studies that expressed fusion proteins containing only
the Dok-1 PH domain and the SHIP-1 catalytic domain function
as constitutive inhibitors of BCR signaling (Akerlund and Cambier,
unpublished).
Although SHIP-1 and Dok-1 phosphorylation can be achieved by
co-aggregation of FcYRIIB with BCR, it is also seen, though to a
much lesser extent, following aggregation of the BCR alone
[9,32,33]. Furthermore, BCR stimulation leads to transient SHIP-1
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gested that in addition to its role in active FccRIIB mediated inhi-
bition, SHIP mediates feedback inhibition of antigen receptor
signaling.
It is unclear how the SHIP-1/Dok-1 circuit is activated by anti-
gen receptor aggregation. Studies of cKit signaling indicate that
Lyn can associate with downstream of kinase (Dok) [35]. This
may facilitate Dok phosphorylation, followed by SHIP recruitment
and phosphorylation, leading ultimately to generation of a mobile
bidentate effector complex equivalent to that predicted to occur
following BCR-FccRIIB co-aggregation.
As noted above SHP-1 functions as mediator of inhibitory
FccRIIB signals under conditions of efﬁcient receptor coaggrega-
tion. Like SHIP-1, SHP-1 also functions as a feedback inhibitor of
BCR signaling. SHP-1 is recruited to phosphorylated ITIM tyrosines
in membrane adaptors, such as CD22 and CD72, that are phosphor-
ylated by Lyn upon BCR aggregation. Active SHP-1 attenuates BCR
signaling via tyrosine dephosphorylation of molecules involved in
positive signaling such as Iga, Igb, CD19, Syk, and BLNK [36–38].
5. SHIP-1/Dok-1 inhibitory circuit in B cell anergy
B cell anergy is likely maintained by multiple inhibitory signal-
ing effectors including the phosphatase and tensin homolog PTEN,
SHP-1 and SHIP-1. PTEN expression is uniquely elevated in anergic
B cells from MD4xML5 anti-HEL mice in which BCR afﬁnity for
autoantigen is extremely high [39]. By association, we hypothesize
that PTEN upregulation may be a unique consequence of chronic B
cell stimulation by very high afﬁnity antigens. Its function may be
uniquely required to reinforce anergy in cells with very high auto-
antigen afﬁnity/avidity because high avidity antigens are very po-
tent inducers of BCR signaling. B cell targeted PTEN knockout mice
do not display an autoimmune phenotype [39]. However, this may
be due to the previously described PTEN requirement for immuno-
globulin class switching [40–42], since clinical signs of autoimmu-
nity require class switched IgG autoantibody.
SHP-1 functions in maintenance of B cell tolerance, presumably
via interactions with ITIM-containing membrane adaptor proteins.
B cell targeted deletion of SHP-1 leads to lupus-like disease at 5–6
months of age and glomerulonephritis at 7–11 months of age [43].
Loss of tolerance in these animals appears to reﬂect loss of anergy
especially since the recently deﬁned anergic B cell compartment is
reduced in size by approximately 40%.
Mounting evidence supports a more major role for SHIP-1 in
maintaining anergy. In support of this, mice with B cell-targeted
SHIP-1 gene ablation exhibit early (2–4 months) onset lupus-like
disease with glomerulonephritis and death by 5–8 months. B cell
ablation of SHIP-1 in the Ars/A1 (anti-ssDNA) immunoglobulin
transgenic mouse lead to loss of anergy and recovery of antigen
receptor mediated calcium signaling. Finally, SHIP-1 and Dok-1
are constitutively tyrosine phosphorylated in naturally occuring
anergic B cells, as well as those from both Ars/A1 and MD4/ML5
transgenic mouse models [44,45] (O’Neil and Cambier, in prepara-
tion). These ﬁndings suggest that chronic activation of the SHIP-1/
Dok-1 circuit maintains anergy by limiting accumulation of
PtdIns(3,4,5)P3 during responses to crossreacting immunogens,
chemokines, BAFF and other ligands that signal via activation of
PI3k.
Maintenance of anergy requires chronic binding of antigen to
BCR [46] suggesting that autoantigen occupied BCR transduce sig-
nals that lead to unresponsiveness. Indeed, anergic B cells exhibit
elevated intracellular free calcium levels and ERK kinase pathway
activation [47], and when autoantigen is removed from BCR by
competitive inhibition with monovalent antigen, levels of intracel-
lular free calcium and phosphorylated ERK are reduced to that seennaïve B cells. In addition, after removal of autoantigen the cell life-
span is increased and the ability to mobilize calcium and up-regu-
late CD86 following BCR stimulation is restored [46]. These data
indicate that chronic BCR signaling is required to maintain anergy.
By extension, this chronic BCR signaling is probably required to
maintain activation of the SHIP-1/Dok-1 inhibitory circuit and
resultant unresponsiveness.
The question arises, how does chronic BCR stimulation lead to
inhibitory SHP-1 and SHIP-1 signaling in anergic B cells? Ongoing
studies in our laboratory are interrogating mechanisms of chronic
signaling by BCR in anergic B cells. These studies have revealed in-
creases in basal Ig-a/b ITAM tyrosine phosphorylation in anergic
cells (O’Neill and Cambier, in preparation). Most importantly, only
monophosphorylation is detectable. This ﬁnding resonates with
previous observations made in studies of signaling competency
of receptors in which only a single ITAM tyrosine is available for
phosphorylation. These studies showed that ITAM monophosph-
orylation induces activation of Lyn but not Syk tyrosine kinases
[6]. The resultant bias towards chronic Lyn activation in anergic
cells could skew signaling towards activation of SHIP-1 and SHP-
1 enforcing unresponsiveness. In support of this possibility, mice
lacking Lyn are autoimmune prone, which suggests Lyn is required
for stimulation of inhibitory signaling circuitry.
Chronic antigen stimulation-induced monophosphorylation of
Iga/Igb ITAMs in anergic B cells is strikingly similar to the ITAMi
signaling described by Blank et al. [1]. Taken at face value, the ma-
jor difference in these signaling pathways is that ITAMi signaling is
proposed to involve only SHP-1 as the operative effector phospha-
tase. However, the possible role of SHIP-1 in ITAMi signaling has
not been explored.
ITAMi signaling involves speciﬁc binding of an ITAM-containing
receptor to low afﬁnity, low avidity, or low valency ligands that
leads to the recruitment of inhibitory effectors such as SHP-1. For
example, FcaRI exhibits ITAMi signaling following monomeric
IgA or anti-FcaRI Fab ligation (low valency interaction) that leads
to incomplete phosphorylation of the associated ITAM containing
receptor FcRc. This incomplete ITAM phosphorylation favors
SHP-1 recruitment over Syk [48,49]. In contrast, multivalent ligand
interaction leads to robust phosphorylation of FcRa associated
FcRc ITAMs and recruitment of Syk [50,51]. Preferential SHP-1
recruitment has also been described in T cells following weakly
binding TCR ligands [52,53].
6. SHIP-1/Dok inhibitory circuit activation by CD4 aggregation;
the exception that may prove the rule
ITAM phosphorylation is mediated primarily by Src-family ki-
nases, and phosphorylated ITAMs further stimulate Src-family ki-
nase activity in a forward feeding loop. It is unclear whether
ITAM phoshorylation plays a role in activation of the SHIP-1/
Dok-1 circuit other than activation of Src-family kinases. A solution
is suggested by studies of the molecular basis of inhibitory signal-
ing by CD4. It has long been known that aggregation of CD4 leads
to generation of molecular signals that inhibit subsequent re-
sponses to TCR aggregation [54]. Under these circumstances, CD4
signals via activation of the Src-family kinase Lck with no involve-
ment of ITAMs. This allowed us to determine whether pITAMs are
actually required for activation of SHIP-1/Dok-1 inhibitory
signaling.
We have found that CD4 aggregation in the absence of TCR in-
duces strong activation of the SHIP-1/Dok-1 inhibitory circuit via
Lck, abrogating subsequent TCR signaling (Waterman and Cambier,
in preparation). This indicates that no intrinsic ITAM (or ITIM)
function is required for inhibitory signaling. Rather, the role of
monophospho-ITAMs is restricted to activation of Src-family ki-
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kinase may be expected to stimulate SHIP-1/Dok-1 inhibitory
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